Kamedis, a provider of advanced botanical solutions for chronic skin disorders, has announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application involving the company's Kamedis Calm Eczema Therapy Cream.
The notice signifies that Kamedis will receive patent protection on the product's proprietary combination of traditional Chinese botanicals, which was developed to treat eczema-related inflammation and infection.
Kamedis Calm Eczema Therapy Cream has been clinically proven to reduce eczema flare-ups by 50% in two weeks, providing significant relief for a condition that affects more than 31 million people in the U.S. including one-third of infants.
The formulation includes Chinese rhubarb, great burnet, tree of heaven, Baikal skullcap, cnidium fruit and licorice extracts -- in conjunction with conventional active and inactive ingredients.
Each botanical in the Kamedis formula contains multiple components that modulate different physiological mechanisms simultaneously, helping restore the natural barrier that protects skin against bacteria and irritants, the company says. This healthy skin ecosystem helps repair the dryness, itchiness, and inflammation associated with eczema -- without steroids, parabens, dyes or fragrances, which means the risk of adverse effects.
A Clinical Trial
A double-blind, randomized clinical trial scheduled for completion in early 2019. It will examine the specific role of the product's botanical ingredients in the healing process - marking the first U.S. clinical study designed to determine the efficacy of traditional Chinese botanicals in commercial dermatologic treatments.
The trial will compare the effectiveness of three products in mitigating eczema symptoms among 108 U.S. children and adults -- Kamedis Calm Eczema Therapy Cream, the Kamedis product without the Chinese botanical formulation, and a competitive OTC brand.
The pending patent on the Kamedis Calm Eczema Therapy will be the first U.S. patent received by the company.